STOCK TITAN
  1. Home
  2. SEC-Filings
  3. ANTX

AN2 Therapeutics, Inc. SEC Filings

ANTX NASDAQ

Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

AN2 Therapeutics (NASDAQ: ANTX) sits at the intersection of cutting-edge infectious-disease science and high-stakes clinical milestones. Whether you are monitoring cash runway for its epetraborole program or gauging management confidence through share purchases, every SEC document carries market-moving clues.

Stock Titan brings these clues forward. Our AI-powered engine scans each AN2 Therapeutics annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material event within seconds, translating dense biotech language into clear, decision-ready takeaways. Looking for AN2 Therapeutics insider trading Form 4 transactions? You’ll receive real-time alerts the moment an executive files. Need the latest status on patient enrollment? The relevant table from the AN2 Therapeutics earnings report filing analysis is highlighted for you.

Here’s what you can uncover:

  • Cash burn trends and partnership revenue inside the AN2 Therapeutics annual report 10-K simplified
  • Dose-response data updates in each AN2 Therapeutics quarterly earnings report 10-Q filing
  • Trial read-outs or FDA designations via AN2 Therapeutics 8-K material events explained
  • Board option grants through AN2 Therapeutics executive stock transactions Form 4
  • Leadership pay packages within the AN2 Therapeutics proxy statement executive compensation

Our platform doesn’t stop at listing documents; it answers the questions professionals actually ask—like “understanding AN2 Therapeutics SEC documents with AI” or “how to interpret ANTX’s Phase 2 cost disclosures.” Skip the 200-page PDFs and move straight to insight with concise AI summaries, expert context, and Form 4 insider transactions real-time feeds—all updated the instant ANTX hits EDGAR.

Filing

[8-K] AN2 Therapeutics, Inc. Reports Material Event

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of AN2 Therapeutics (ANTX)?

The current stock price of AN2 Therapeutics (ANTX) is $1.06 as of June 30, 2025.

What is the market cap of AN2 Therapeutics (ANTX)?

The market cap of AN2 Therapeutics (ANTX) is approximately 32.3M.

What is the core mission of AN2 Therapeutics, Inc.?

AN2 Therapeutics is dedicated to developing transformational medicines for patients suffering from rare, chronic, and serious infectious diseases. Their mission is rooted in addressing global unmet needs in the field of infectious disease treatment.

Which therapeutic areas does the company focus on?

The company primarily focuses on infectious diseases, with special emphasis on rare and chronic conditions such as non-tuberculous mycobacterial lung disease. Their research aims to fill critical gaps in current treatment options.

How does AN2 Therapeutics generate its revenue?

As a clinical-stage biopharmaceutical firm, revenue generation will primarily depend on the successful progression of its investigational treatments through clinical trials, partnerships, and licensing arrangements, rather than on broad commercial sales at this stage.

What distinguishes AN2 Therapeutics from other biopharma companies?

Their focus on developing once-daily oral therapies for complex infectious diseases and their methodical research approach set them apart. The company’s experienced leadership and commitment to global health further underscore their distinctive position in the industry.

What kind of research and development strategy does the company adopt?

The company employs a rigorous, structured R&D strategy that integrates preclinical studies, translational research, and well-designed clinical trials. This process ensures that each development stage meets high scientific and regulatory standards.

How does AN2 Therapeutics ensure the safety and efficacy of its treatments?

Through adherence to stringent regulatory standards and robust clinical trial designs, the company ensures comprehensive evaluation of its drug candidates. Its focus on pharmacodynamics, pharmacokinetics, and patient safety is integral to its operational framework.

What is the significance of the company’s product candidate for NTM lung disease?

The investigational product candidate represents a novel, once-daily oral treatment approach for patients with non-tuberculous mycobacterial lung disease. This focus addresses an area with significant unmet clinical needs, highlighting the company’s commitment to innovation in infectious disease therapy.

In what ways does the company demonstrate industry expertise?

AN2 Therapeutics leverages its experienced leadership and comprehensive clinical R&D methodologies to address complex infectious diseases. Their transparent adherence to international quality standards and scientific rigor underscores their deep industry expertise.
Stock ANTX logo
AN2 Therapeutics, Inc.

NASDAQ:ANTX

ANTX Rankings

#5335 Ranked by Market Cap
N/A Ranked by Dividends

ANTX Stock Data

32.29M
23.16M
22.5%
46.31%
0.38%
Biotechnology
Pharmaceutical Preparations
Link
United States
MENLO PARK